FDA Raises Doubt on Lung Cancer Drug by AstraZeneca

AstraZeneca's lung cancer immunotherapy, Imfinzi, is teetering on the brink of approval. The FDA has expressed significant reservations about the drug's efficacy and safety when used both before and after surgery.

Key concerns center on the lack of definitive evidence demonstrating the individual contributions of Imfinzi's pre- and post-operative administration to patient outcomes. Additionally, the drug's performance in a pivotal trial did not decisively outperform a competing therapy, casting doubt on its overall benefit.

The FDA is also wary of potential overtreatment risks associated with the drug's use in both phases of care. The upcoming advisory committee meeting will be a critical juncture, determining whether Imfinzi can overcome these hurdles and secure regulatory approval. Investors and patients alike will be watching closely as the fate of this promising drug hangs in the balance.